News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. (RNN) Announces Initial Results From Phase I Trial Of Supinoxintm (RX-5902) For Solid Cancer Tumors



3/11/2014 9:08:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES